My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia
Status:
Unknown status
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The patient receive 2 different drug combinations on this study. The first combination will
consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate,
doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The
second combination will consist of another intensive chemotherapy regimen (methotrexate and
Ara-C [cytarabine]).